The latest generation technology used by Mevopur additives reduces cycle times by improving rate of crystallization and the crystallization temperature versus conventional technology in homopolymer and random copolymer polypropylene (PP) and in high density and low density polyethylene (PE).
Mevopur nucleants make the polymers more rigid without degrading impact strength and aids converters to create thinner-walled part sections and generate raw material savings.
Mevopur nucleants can also reduce molding defects caused by anisotropic shrinkage, such as warping and sink marks.
Clariant Global Segment Medical and Pharmaceutical head Steve Duckworth said extending the Mevopur brand with a range of additives further enhances the support offered by Clariant to the medical devices and pharmaceutical industries.